Acasti Pharma Inc. (ACST)’s Financial Results Comparing With Acer Therapeutics Inc. (NASDAQ:ACER)

Both Acasti Pharma Inc. (NASDAQ:ACST) and Acer Therapeutics Inc. (NASDAQ:ACER) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acasti Pharma Inc. 2 0.00 71.50M -1.22 0.00
Acer Therapeutics Inc. 3 0.00 3.46M -2.71 0.00

Demonstrates Acasti Pharma Inc. and Acer Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.


Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Acasti Pharma Inc. 3,626,312,319.32% 0% 0%
Acer Therapeutics Inc. 122,482,211.76% -67.4% -61.7%

Analyst Ratings

The following table shown below contains the ratings and recommendations for Acasti Pharma Inc. and Acer Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acasti Pharma Inc. 0 0 1 3.00
Acer Therapeutics Inc. 0 0 1 3.00

Acasti Pharma Inc.’s upside potential currently stands at 316.67% and an $7.75 average target price. Acer Therapeutics Inc. on the other hand boasts of a $48 average target price and a 1,543.84% potential upside. Based on the results shown earlier, Acer Therapeutics Inc. is looking more favorable than Acasti Pharma Inc., analysts opinion.

Institutional & Insider Ownership

Acasti Pharma Inc. and Acer Therapeutics Inc. has shares owned by institutional investors as follows: 4.02% and 61.1%. Insiders owned roughly 13.28% of Acasti Pharma Inc.’s shares. Insiders Comparatively, owned 0.3% of Acer Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acasti Pharma Inc. 2.99% 107.76% 181.87% 129.52% 338.18% 189.7%
Acer Therapeutics Inc. 2.4% -23.92% -84.35% -87.67% -84.67% -85.14%

For the past year Acasti Pharma Inc. has 189.7% stronger performance while Acer Therapeutics Inc. has -85.14% weaker performance.


On 7 of the 10 factors Acasti Pharma Inc. beats Acer Therapeutics Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.